Curis, Inc. disclosed that its frontline acute myeloid leukemia (AML) triplet study (CA‑4948‑104) achieved a 62.5% undetectable minimal residual disease (uMRD) rate in the first eight patients enrolled, an increase from the 50% rate reported earlier in the year.
The study combines the company’s oral IRAK4/FLT3 inhibitor emavusertib with venetoclax and azacitidine in patients who had reached complete remission on venetoclax‑azacitidine but remained MRD‑positive. The 62.5% uMRD rate—5 of 8 patients—was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition held in Orlando, Florida, from December 6‑9 2025.
Achieving uMRD is a key surrogate for long‑term survival in AML, and the improvement from 50% to 62.5% suggests the triplet regimen may provide deeper disease eradication than standard therapy alone. The data were updated as of October 12 2025, reflecting the most recent patient cohort at the time of presentation.
Financially, Curis reported a net loss of $7.7 million for the third quarter of 2025, a reduction from the $10.1 million loss in the same quarter a year earlier. Cash and cash equivalents stood at $9.1 million as of September 30 2025, giving the company an estimated runway into the first quarter of 2026 and underscoring the need for continued capital to fund ongoing clinical development.
Strategically, the positive uMRD data support Curis’s plan to expand emavusertib beyond its monotherapy programs in primary central nervous system lymphoma and AML. The company views the triplet as a potential candidate for future regulatory submissions, positioning it to capture a larger share of the AML market if the clinical benefit translates into regulatory approval.
CEO James Dentzer highlighted the results as “very promising,” noting that the data reinforce the company’s belief that emavusertib can enhance the efficacy of venetoclax‑azacitidine in a difficult‑to‑treat patient population. The announcement aligns with Curis’s broader strategy to leverage its dual‑inhibition platform across multiple indications while managing the financial constraints inherent to a development‑stage biopharma company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.